Filtern
Dokumenttyp
- Wissenschaftlicher Artikel (24)
- Postprint (6)
- Sonstiges (2)
- Rezension (1)
Sprache
- Englisch (33)
Gehört zur Bibliographie
- ja (33)
Schlagworte
- acid sphingomyelinase (9)
- ceramide (9)
- acid ceramidase (5)
- Farber disease (3)
- Sphingolipids (3)
- lysosomal storage disorders (3)
- sphingomyelin (3)
- 1-aminodecylidene bis-phosphonic acid (2)
- Acid sphingomyelinase (2)
- Ceramide (2)
- Pseudomonas aeruginosa (2)
- Smpd1 (2)
- amitriptyline (2)
- anxiety-like behavior (2)
- bisphosphonates (2)
- cerami-des (2)
- ceramides (2)
- chronic psychosocial stress (2)
- chronic subordinate colony housing (CSC) (2)
- depressive-like behavior (2)
- enzymology (2)
- forebrain (2)
- functional inhibitors of acid sphin-gomyelinase (2)
- lipid metabolism (2)
- liver metabolism (2)
- lysosomal hydrolases (2)
- lysosome (2)
- mass spectrometry (2)
- serine palmitoyltransferase (2)
- sphingolipid de novo synthesis (2)
- sphingolipid metabolism (2)
- sphingolipids (2)
- stable-isotope labeling (2)
- (2E)-hexadecenal (1)
- (2E)-hexadecenoic acid (1)
- Acinetobacter baumannii (1)
- Adipose tissue (1)
- Alcohol dependence (1)
- Anxiety (1)
- Autotaxin (1)
- COPD (1)
- Caenorhabditis elegans (1)
- Cardiovascular (1)
- Case-control study (1)
- Chemoprophylaxis (1)
- Clinical (1)
- Coating (1)
- Cystic fibrosis (1)
- DAIH (1)
- Depression (1)
- Derivatization (1)
- Diagnostic (1)
- Disease (1)
- Dopamine (1)
- EDC (1)
- Glycerophospholipids (1)
- HPLC-ESI-QTOF (1)
- Hepatic insulin resistance (1)
- Inhalation (1)
- Insulin signaling (1)
- Ischemia/reperfusion (1)
- Isotope-dilution (1)
- Isotope-dilution analysis (1)
- LPA(3) receptor subtype (1)
- Liquid chromatography-tandem mass spectrometry (1)
- Liver injury (1)
- Lysophosphatidic acid (1)
- Lysophosphatidylcholines (1)
- Mass spectrometry (1)
- Phosphatidylcholines (1)
- Phosphatidylinositols (1)
- Plasma (1)
- Plasmalogens (1)
- Plastic surfaces (1)
- Serotonin (1)
- Sphingomyelin (1)
- Sphingosine (1)
- Sphingosine 1-phosphate (1)
- Sphingosine kinase (1)
- Staphylococcus aureus (1)
- Tandem mass spectrometry (1)
- Transplantation (1)
- Trauma (1)
- Traumatic brain injury (1)
- Venous thromboembolism (1)
- Ventilation (1)
- blood banking (1)
- cystic fibrosis (1)
- extinction (1)
- hepatic ischemia-reperfusion (1)
- hippocampus (1)
- homolog (1)
- injury (1)
- integrins (1)
- ischemia/reperfusion (1)
- liver-regeneration (1)
- long chain base (1)
- lung infection (1)
- lung inflammation (1)
- mechanisms (1)
- mice (1)
- microparticle (1)
- neutrophil (1)
- operant behavior (1)
- platelets (1)
- recovery (1)
- sphingosine (1)
- tumor-metastasis (1)
Human and murine studies identified the lysosomal enzyme acid sphingomyelinase (ASM) as a target for antidepressant therapy and revealed its role in the pathophysiology of major depression. In this study, we generated a mouse model with overexpression of Asm (Asm-tg(fb)) that is restricted to the forebrain to rule out any systemic effects of Asm overexpression on depressive-like symptoms. The increase in Asm activity was higher in male Asm-tg(fb) mice than in female Asm-tg(fb) mice due to the breeding strategy, which allows for the generation of wild-type littermates as appropriate controls. Asm overexpression in the forebrain of male mice resulted in a depressive-like phenotype, whereas in female mice, Asm overexpression resulted in a social anxiogenic-like phenotype. Ceramides in male Asm-tg(fb) mice were elevated specifically in the dorsal hippocampus. mRNA expression analyses indicated that the increase in Asm activity affected other ceramide-generating pathways, which might help to balance ceramide levels in cortical brain regions. This forebrain-specific mouse model offers a novel tool for dissecting the molecular mechanisms that play a role in the pathophysiology of major depression.
Human and murine studies identified the lysosomal enzyme acid sphingomyelinase (ASM) as a target for antidepressant therapy and revealed its role in the pathophysiology of major depression. In this study, we generated a mouse model with overexpression of Asm (Asm-tg(fb)) that is restricted to the forebrain to rule out any systemic effects of Asm overexpression on depressive-like symptoms. The increase in Asm activity was higher in male Asm-tg(fb) mice than in female Asm-tg(fb) mice due to the breeding strategy, which allows for the generation of wild-type littermates as appropriate controls. Asm overexpression in the forebrain of male mice resulted in a depressive-like phenotype, whereas in female mice, Asm overexpression resulted in a social anxiogenic-like phenotype. Ceramides in male Asm-tg(fb) mice were elevated specifically in the dorsal hippocampus. mRNA expression analyses indicated that the increase in Asm activity affected other ceramide-generating pathways, which might help to balance ceramide levels in cortical brain regions. This forebrain-specific mouse model offers a novel tool for dissecting the molecular mechanisms that play a role in the pathophysiology of major depression.
Background: The pathophysiology behind the subacute but persistent hypercoagulable state after traumatic brain injury (TBI) is poorly understood but contributes to morbidity induced by venous thromboembolism. Because platelets and their microvesicles have been hypothesized to play a role in post-traumatic hypercoagulability, administration of commonly used agents may ameliorate this coagulability. We hypothesized that utilization of aspirin, ketorolac, amitriptyline, unfractionated heparin, or enoxaparin would modulate the platelet aggregation response after TBI. Methods: Concussive TBI was induced by weight drop. Mice were then randomized to receive aspirin, ketorolac, amitriptyline, heparin, enoxaparin, or saline control at 2 and 8 h after TBI. Mice were sacrificed at 6 or 24 h after injury to determine coagulability by rotational thromboelastometry (ROTEM), platelet function testing with impedance aggregometry, and microvesicle enumeration. Platelet sphingolipid metabolites were analyzed by mass spectrometry. Results: ROTEM demonstrated increased platelet contribution to maximum clot firmness at 6 h after TBI in mice that received aspirin or amitriptyline, but this did not persist at 24 h. By contrast, adenosine diphosphate- and arachidonic acid-induced platelet aggregation at 6 h was significantly lower in mice receiving ketorolac, aspirin, and amitriptyline compared with mice receiving saline at 6 h after injury and only arachidonic acid-initiated platelet aggregation was decreased by aspirin at 24 h. There were no differences in microvesicle production at either time point. Platelet sphingosine-1-phosphate levels were decreased at 6 h in the group receiving amitriptyline and increased at 24 h along with platelet ceramide levels at 24 h in the amitriptyline group. Conclusion: After TBI, amitriptyline decreased platelet aggregability and increased contribution to clot in a manner similar to aspirin. The amitriptyline effects on platelet function and sphingolipid metabolites may represent a possible role of the acid sphingomyelinase in the hypercoagulability observed after injury. In addition, inhibition of platelet reactivity may be an underappreciated benefit of low molecular weight heparins, such as enoxaparin. (C) 2019 Elsevier Inc. All rights reserved.